GlassScriptPhysician profile
Shawn George Abraham
NPI 1184940108
$1,199.51
in general payments reported to CMS, 2019-2025
15 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $22.90 · 2021: $217 · 2022: $99.71 · 2023: $181 · 2024: $159 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.81 | 2021-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $219.44 | 2019-2023 | |
| Aurinia Pharma U.S., INC. | $138.66 | 2021 | |
| Glaxosmithkline, LLC. | $122.10 | 2024 | Nucala |
| Amgen INC. | $72.36 | 2019-2020 | |
| Depuy Synthes Sales INC. | $42.71 | 2025 | Orthovisc, Peak, Monovisc |
| Horizon Therapeutics Plc | $22.53 | 2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $18.67 | 2022 | |
| Fresenius Kabi USA, LLC | $15.33 | 2023 | Idacio |
| Organon LLC | $15.30 | 2023 | Hadlima, Renflexis |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2022 | |
| Pfizer INC. | $14.10 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.75 | 2023 | Orencia |
| Ucb, INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.